RESUMO

Resumo Fundamento Recentemente, foi demonstrado que o alopurinol, um inibidor da xantina oxidase, possui propriedades cardiovasculares e anti-isquêmicas e pode ser uma opção de agente antianginoso metabólico. Objetivo O objetivo do presente estudo foi avaliar o efeito antianginoso do alopurinol como terceiro medicamento para pacientes com doença arterial coronariana (DAC) estável. Métodos Trata-se de um ensaio clínico randomizado entre 2018 e 2020 incluindo pacientes com DAC que mantiveram angina apesar da otimização inicial com betabloqueadores e bloqueadores dos canais de cálcio. Os indivíduos foram randomizados 1:1 para 300 mg de alopurinol 2 vezes ao dia ou 35 mg de trimetazidina 2 vezes ao dia. O desfecho principal foi a diferença no domínio da frequência da angina do Questionário de Angina de Seattle (QAS-FA). Foram considerados estatisticamente significativos valores de probabilidade (p) < 0,05. Resultados Foram incluídos 108 pacientes na fase de randomização, com 54 (50%) no grupo alopurinol e 54 (50%) no grupo trimetazidina. Seis (5,6%) indivíduos, 3 de cada grupo, foram perdidos no seguimento para o desfecho primário. Nos grupos de alopurinol e trimetazidina, as pontuações medianas do QAS-FA foram 50 (30,0 a 70,0) e 50 (21,3 a 78,3), respectivamente. Em ambos os grupos, a pontuação do QAS-FA melhorou, mas a mediana da diferença em relação à linha de base foi menor no grupo alopurinol (10 [0 a 30] versus 20 [10 a 40]; p < 0,001), assim como a média da diferença na pontuação total do QAS (12,8 ± 17,8 versus 21,2 ± 15,9; p = 0,014). Conclusão Tanto o alopurinol quanto a trimetazidina melhoraram o controle dos sintomas de angina; no entanto, a trimetazidina apresentou um ganho maior em relação à linha de base. Registro Brasileiro de Ensaios Clínicos - Número de Registro RBR-5kh98y

Abstract Background Recently, it was demonstrated that allopurinol, a xanthine oxidase inhibitor, has cardiovascular and anti-ischaemic properties and may be a metabolic antianginal agent option.Objective: The objective of this study was to evaluate the antianginal effect of allopurinol as a third drug for patients with stable coronary artery disease (CAD). Methods This was a randomized clinical trial between 2018 and 2020 including patients with CAD who maintained angina despite initial optimization with beta-blockers and calcium channel blockers. The individuals were randomized 1:1 to 300 mg of allopurinol twice daily or 35 mg of trimetazidine twice daily. The main outcome was the difference in the angina frequency domain of the Seattle Angina Questionnaire (SAQ-AF). A probability (p) value < 0.05 was considered statistically significant. Results A hundred and eight patients were included in the randomization phase, with 54 (50%) in the allopurinol group and 54 (50%) in the trimetazidine group. Six (5.6%) individuals, 3 from each group, were lost to follow-up for the primary outcome. In the allopurinol and trimetazidine groups, the median SAQ-AF scores were 50 (30.0 to 70.0) and 50 (21.3 to 78.3), respectively. In both groups, the SAQ-AF score improved, but the median of the difference compared to baseline was lower in the allopurinol group (10 [0 to 30] versus 20 [10 to 40]; p < 0.001), as was the mean of the difference in the total SAQ score (12.8 ± 17.8 versus 21.2 ± 15.9; p = 0.014). Conclusion Both allopurinol and trimetazidine improved the control of angina symptoms; however, trimetazidine presented a greater gain compared to baseline. Brazilian Registry of Clinical Trials - Registration Number RBR-5kh98y

RESUMO

El síndrome de DRESS (por sus siglas en inglés Drug Reaction with Eosinophilia and Systemic Symptoms) representa una farmacodermia grave con diferentes manifestaciones clínicas y paraclínicas secundarias a una reacción de hipersensibilidad farmacológica. Su incidencia exacta es desconocida pero se estima entre 1 a 1000 y 1 a 10000 casos de exposición a fármacos asociados. Se caracteriza por dermatosis generalizada extensa en conjunto con afección orgánica, linfadenopatia, eosinofilia y linfocitosis atípica. Entre los fármacos comúnmente asociados se encuentran anticomiciales aromáticos, carbamazepina, sulfonamidas y el alopurinol. Mediante el uso de la puntuación RegiSCAR es posible confirmar o descartar una sospecha de diagnóstico. El tratamiento depende de la severidad de presentación incluyendo esteroides tópicos hasta esteroide sistémico de duración variable dependiendo respuesta clínica y bioquímica. Se reporta tasas de mortalidad del 10 al 20% siendo la insuficiencia hepática la principal causa de muerte en estos pacientes. Se presenta el caso de un paciente femenino de 71 años de edad que, posterior a tratamiento con alopurinol, debuta con eritrodermia secundaria a Síndrome de DRESS.

DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) represents severe pharmacodermia with different clinical and paraclinical manifestations secondary to a drug hypersensitivity reaction. The exact incidence is unknown, but it is estimated to be between 1 in 1,000 and 1 in 10,000 cases of exposure to associated drugs. It is characterized by extensive generalized dermatosis, in conjunction with organic involvement, lymphadenopathy, eosinophilia, and atypical lymphocytosis. Commonly associated drugs include aromatic anticonvulsants, carbamazepine, sulfonamides, and allopurinol. By using the RegiSCAR score, it is possible to confirm or rule out a suspected diagnosis. Treatment depends on the severity of presentation, including topical steroids to systemic steroids of variable duration, depending on clinical and biochemical responses. Mortality rates of 10 - 20% have been reported, with liver failure being the main cause of death in these patients. We present the case of a 71-year-old female patient who, after treatment with allopurinol, developed erythroderma secondary to DRESS Syndrome.

RESUMO

Contexto: el ácido úrico es el producto final de la degradación de las purinas en los primates, en condiciones normales es un agente antioxidante endógeno y participa en varias vías fisiológicas, sin embargo, cuando los niveles séricos de urato se incrementan, estos participan en el desarrollo de diversas enfermedades. Desde el siglo XIX se conoce de la asociación entre hiperuricemia y daño renal, aunque ninguna guía de manejo recomienda el uso de fármacos hipouricemiantes en pacientes asintomáticos, en algunos casos especiales, el manejo farmacológico beneficiará a pacientes con hiperuricemia, brindando protección al riñón y disminuyendo el riesgo de desarrollar enfermedad renal terminal. Objetivo: describir la relación entre hiperuricemia y daño renal, y analizar los casos en los que el manejo de esta condición con medicamentos resultará en un beneficio para el riñón de los pacientes. Metodología: revisión de la literatura sobre la participación de la hiperuricemia en el daño renal y análisis de los artículos revisados. Resultados: el manejo de la hiperuricemia asintomática puede proteger el riñón en algunas situaciones específicas. Conclusiones: hay situaciones específicas para la disminución de los niveles séricos de ácido úrico.

Background: Uric acid is the end product of purine degradation in primates, under normal conditions it is an endogenous antioxidant agent and participates in several physiological pathways. However, when serum urate levels are increased, they participate in the development of various diseases. Since the nineteenth century, the association between hyperuricemia and kidney damage has been known. Although no management guideline recommends the use of hypouricemic drugs in asymptomatic patients, in some special cases pharmacological management will benefit patients with hyperuricemia, providing protection to the kidney and decreasing the risk of developing end-stage renal disease. Purpose: To describe the relationship between hyperuricemia and kidney damage, and to analyze the cases in which the management of this condition with medications will result in a benefit for the kidney of patients. Methodology: Review of the literature on the involvement of hyperuricemia in kidney damage, analysis of the reviewed articles. Results: Management of asymptomatic hyperuricemia may protect the kidney in some specific situations. Conclusions: There are specific situations for the decrease of serum uric acid levels.

RESUMO

Introducción:El síndrome de lisis tumoral (SLT) es una emergencia oncológica, que produce alteraciones en el metabolismo, causando manifestaciones clínicas y trastornos bioquímicos que ponen en peligro la vida del paciente.El objetivo del presente estudio fue identificar las características clínicas, de laboratorio y tratamiento del SLT, en pacientes pediátricos onco-lógicos, del Instituto del Cáncer SOLCA-Cuenca, en el periodo 2010 ­2020.Materiales y métodos:En este estudio se identificó las características del SLT, en pacientes pediátricos oncológicos, del Instituto del Cáncer SOLCA-Cuenca, en el periodo 2010 ­2020, a través de un estudio de tipo descriptivo-observacional.Resultados:Seincluyó 463 historias clínicas, en el cual se obtuvo que el SLT tuvo una frecuen-cia del 5.61 %, con predominio del sexo masculino (57.7%) y con una edad media de 7 ± 1.29 años. La presentación clínica más observada fue la deshidratación con náusea, vómito y dia-rrea (57.7%). Las alteraciones de laboratorio más frecuentes fueron la hiperuricemia y la hi-pocalcemia, con un 76.9 %y un 73.1 %respectivamente. La Leucemia linfoblástica aguda (LLA) fue el diagnósticooncológico con más casos (61.5 %). Los pilares del tratamiento fue-ron la hiperhidratación y el uso de alopurinol, utilizados en el 100% y un 80.8 %respectiva-mente.Conclusión:El SLT afectó más frecuentemente a varones, con diagnóstico de leucemia, ma-nifestaciones clínicas digestivas y alteraciones de laboratorio (hiperuricemia e hipocalcemia). El tratamiento empleado resultó eficaz y se basó en lo recomendado por la literatura médica

Introduction:Tumor lysis syndrome (TLS) is an oncological emergency that results in meta-bolic alterations, causing clinical manifestations and biochemical disorders that endanger pa-tients' lives. The objective of the present study was to identify the clinical, laboratory, and treat-ment characteristics of TLSsin pediatric oncology patients at the SOLCA-Cuenca Cancer Ins-titute from 2010­2020.Materials and methods: In this study, the characteristics of TLS were identified in pediatric oncology patients at the SOLCA-Cuenca Cancer Institute from 2010 to 2020 through a des-criptive observational study.Results: A total of463 medical records were included. TLSs were associated witha frequency of 5.61%, with a predominance of males(57.7%) and a mean age of 7 ± 1.29 years. The most commonclinical presentation was dehydration with nausea, vomiting, and diarrhea (57.7%). The most frequent laboratory alterations were hyperuricemia and hypocalcemia, with 76.9% and 73.1%,respectively. The oncological diagnosis was acutelymphoblastic leukemia (ALL) in most patients(61.5%). The pillars of treatment were hyperhydration and allopurinol, used in 100% and 80.8%, respectively.Conclusion: TLSsmore frequently affectmen with a diagnosis of leukemia, digestive clinical manifestations, orlaboratory alterations (hyperuricemia and hypocalcemia). The treatment used was effective and based on what the medical literature recommended

Assuntos

RESUMO

Background: Canine visceral leishmaniasis causes several clinical signs, such as lymphadenomegaly, exfoliative dermatitis, ulcerative skin lesions, and lameness. The most commonly reported locomotor changes are claudication, edema, arthralgia, joint stiffness, and muscle atrophy. Radiographic exam revealed cortical and medullary destruction, increase, or decrease in medullary opacity, proliferative periosteal reaction, osteolysis, collapse of joint spaces and soft tissue edema are observed. The aim of this report is to describe the clinical and radiographic evolution of a case of erosive polyarthritis associated with leishmaniasis in a dog before, during and after treatment with miltefosine. Case: A 7-month-old mixed-breed dog was attended due pain and limited mobility. In the orthopedic evaluation, joint swelling, stiffness, and increased pain sensitivity of the four limbs, as well as neck stiffness, were noted. Radiographic examination showed joint changes compatible with edema, with increased volume and radiopacity of the soft tissues adjacent to the joints. The segments of the patient's spine showed more severe bone alterations, the cervical spine being one of the most affected regions, with multiple bone proliferations throughout the vertebral body, especially in the ventral portion (spondylosis), compatible with polyarthritis due to leishmaniasis. Due to the suspicion, lymph node and spleen cytology was performed, confirming the diagnosis. Hematological examination revealed anemia, leukopenia due to lymphopenia and thrombocytopenia in addition to increased AST (79,4 U/L; reference: 6,2 - 13 U/L), creatine kinase (517,6 U/L; reference: 1,5 - 28,4 U/L), lactate dehydrogenase (688,4 IU/L; reference: 45 - 233 IU/L) and hyperproteinemia (7,34 g/dL; reference: 5,4 - 7,1 g/dL). Treatment with miltefosine, allopurinol, domperidone, prednisone, gabapentin and dipyrone was started. Reassessments were performed monthly for 3 consecutive months. Hematological examinations showed improvement, with resolution of anemia and thrombocytopenia, and a marked decrease in creatine kinase values. Thus, it is evident that the dog did not develop liver or kidney changes during treatment. During the treatment and monitoring in this period, the dog had a clinical improvement, which started to walk without pain. In addition, joint swellings were no longer present, however, there was no improvement in the radiographic evaluation of the joints. Discussion: Clinical signs of the locomotor system are compatible with those described in animals that had osteoarticular manifestations associated with leishmaniasis, such as arthralgia, edema, and joint stiffness. In the present report, treatment with miltefosine associated with allopurinol resulted in an improvement in the clinical picture, and this therapy is therefore promising in dogs with polyarthritis due to leishmaniasis. A case published in human medicine demonstrated the intra-articular absorption capacity of this drug. There is only one study to date that describes the radiographic evolution of a dog with arthritis due to leishmaniasis after treatment with miltefosine and allopurinol. In this case described, the dog reported remained with the osteoarticular lesions after treatment, although clinical improvement was observed, as in our report. The use of miltefosine and allopurinol are in accordance with stage II staging for leishmaniasis. In this study, although there was no improvement in the radiographic examinations, the treatment was effective in the remission of the animal's clinical condition.

Assuntos

RESUMO

Canine visceral leishmaniasis is an endemic zoonosis in Brazil. Dogs are the main hosts in urban environments. The treatment has gained popularity since the Brazilian government authorized miltefosine for canine treatment. The aim of this study was to investigate the clinical and parasitological impact of short-term treatment with miltefosine and allopurinol, alone and in combination. We evaluated the ability of pharmacotherapy to reduce clinical signs of disease, antibody levels using the indirect fluorescence antibody test (IFAT) and skin parasite load via qPCR after 28 days of treatment. The therapeutic protocols promoted a significant decline in clinical signs and in the skin parasite load in dogs (p < 0.01). We observed a moderate correlation between the skin parasite load and the clinical score in all three treatment groups (r > 0.5) Antibody levels did not decrease in this short period. It was concluded that the treatment with allopurinol reduced the number of parasites in the skin of dogs with visceral leishmaniasis in the short term. However, its efficiency is potentiated when associated with miltefosine.(AU)

A leishmaniose visceral canina é uma zoonose endêmica no Brasil. Os cães são os principais hospedeiros em ambientes urbanos. O tratamento ganhou popularidade desde que o governo brasileiro autorizou a miltefosina para tratamento canino. O objetivo deste estudo foi investigar o impacto clínico e parasitológico do tratamento a curto prazo com miltefosina e alopurinol, isoladamente e/ou em combinação. Foi avaliada a capacidade da farmacoterapia em reduzir os sinais clínicos da doença e também os níveis de anticorpos, usando-se o teste de anticorpos de fluorescência indireta (RIFI) e a carga parasitária na pele, via qPCR, após 28 dias de tratamento. Os protocolos terapêuticos promoveram declínio significativo dos sinais clínicos e da carga parasitária na pele dos cães (p < 0,01). Foi observada uma correlação moderada entre a carga parasitária da pele e o escore clínico em todos os três grupos de tratamento (r > 0,5). Já os níveis de anticorpos não diminuíram nesse curto período. Concluiu-se que o tratamento com alopurinol, em curto prazo, reduziu a quantidade de parasitos na pele dos cães com leishmaniose visceral. No entanto, sua eficiência é potencializada quando associada a miltefosina.(AU)

Assuntos

RESUMO

Abstract Hyperuricemia is common in chronic kidney disease (CKD) and may be present in 50% of patients presenting for dialysis. Hyperuricemia can be secondary to impaired glomerular filtration rate (GFR) that occurs in CKD. However, hyperuricemia can also precede the development of kidney disease and predict incident CKD. Experimental studies of hyperuricemic models have found that both soluble and crystalline uric acid can cause significant kidney damage, characterized by ischemia, tubulointerstitial fibrosis, and inflammation. However, most Mendelian randomization studies failed to demonstrate a causal relationship between uric acid and CKD, and clinical trials have had variable results. Here we suggest potential explanations for the negative clinical and genetic findings, including the role of crystalline uric acid, intracellular uric acid, and xanthine oxidase activity in uric acid-mediated kidney injury. We propose future clinical trials as well as an algorithm for treatment of hyperuricemia in patients with CKD.

Resumo A hiperuricemia é comum na doença renal crônica (DRC) e pode estar presente em até 50% dos pacientes que se apresentam para diálise. A hiperuricemia pode ser secundária ao comprometimento da taxa de filtração glomerular (TFG) que ocorre na DRC. No entanto, ela também pode preceder o desenvolvimento da doença renal e mesmo prever uma DRC incidente. Estudos experimentais de modelos hiperuricêmicos descobriram que tanto o ácido úrico solúvel quanto o cristalino podem causar danos renais significativos, caracterizados por isquemia, fibrose tubulointersticial e inflamação. Entretanto, a maioria dos estudos de randomização Mendeliana falhou em demonstrar uma relação causal entre o ácido úrico e a DRC, e os ensaios clínicos têm apresentado resultados variáveis. Aqui sugerimos explicações potenciais para os achados clínicos e genéticos negativos, incluindo o papel do ácido úrico cristalino, do ácido úrico intracelular e da atividade da xantina oxidase na lesão renal mediada por ácido úrico. Propomos ensaios clínicos futuros, bem como um algoritmo para o tratamento de hiperuricemia em pacientes com DRC.

Assuntos

RESUMO

RESUMEN Objetivo: Identificar las características clínicas de los pacientes con gota y la forma de utilización de los medicamentos antigotosos en Colombia. Métodos: Estudio de corte transversal en el que se analizaron 310 historias clínicas de pacientes atendidos en el último trimestre del 2016 y que recibieron un medicamento antigotoso. Se identificaron variables sociodemográficas, clínicas, farmacológicas, comorbilidades y paraclínicas. Para cada medicamento antigotoso se determinó si el uso fue según las recomendaciones aprobadas por la Federal Drug Administration (FDA). Se realizaron análisis descriptivos, bivariados y multivariados. Resultados: Se evaluaron pacientes de 14 diferentes ciudades de Colombia, con un predominio masculino del 70,3% (n = 218) y una mediana de edad de 64 arios (RIC: 26-94 arios). El antigotoso más frecuentemente utilizado fue alopurinol (n = 255; 82,3%), seguido de colchicina (n = 54; 17,4%). Los diagnósticos hallados como indicación fueron: hiperuricemia (n = 181; 58,4%), gota (n = 34; 11%), artritis gotosa (n = 28; 9%). El 74,5% (n = 231) de las prescripciones tenía un uso aprobado según la FDA, especialmente alopurinol en el manejo de gota e hiperuricemias, mientras que colchicina se encontró siendo utilizada en indicaciones no aprobadas (n = 44; 81,4%). Las comorbilidades más frecuentes fueron hipertensión (68,4%) y dislipidemia (55,8%). Conclusiones: Los pacientes con gota en tratamiento farmacológico tienen una elevada frecuencia de comorbilidades cardiovasculares, y están siendo tratados con alopurinol para la prevención a largo plazo, mientras que una menor proporción recibe colchicina que comúnmente es utilizada para indicaciones no aprobadas por las agencias reguladoras.

ABSTRACT Objective: To identify the clinical characteristics of patients with gout, and the prescription patterns of anti-gout medications in Colombia. Methods: Cross-sectional study, that analysed the data from 310 medical records of patients treated in the last quarter of 2016, and who received an anti-gout medication. Sociodemographic, clinical, pharmacological, comorbidities, and paraclinical variables were identified. For each anti-gout drug used, it was determined whether the use was in accordance with Federal Drug Administration (FDA) approved recommendations. Descriptive, bivariate and multivariate analyses were performed. Results: Patients from 14 different cities in Colombia were evaluated, with a male predominance of 70.3% (n = 218) and a median age of 64 years (RIC: 26-94 years). The most frequently used anti-gout medication was allopurinol (n = 255; 82.3%), followed by colchicine (n = 54; 17.4%). The main diagnoses found as an indication were: hyperuricaemia (n=181, 58.4%), gout (n = 34; 11.0%), and gouty arthritis (n = 28; 9.0%). Almost three-quarters (74.5%; n = 231) of the prescriptions had an approved use according to the FDA, especially allopurinol in the management of gout and hyperuricaemia, while colchicine was found to be used in unapproved indications (n = 44, 81.4%). The most frequent comorbidities were hypertension (68.4%) and dyslipidaemia (55.8%). Conclusions: Patients with gout who are under pharmacological treatment have a high frequency of cardiovascular comorbidities. They were being treated with allopurinol for long-term prevention, while a smaller proportion received colchicine, which is often used for indications not approved by regulatory agencies.

Assuntos

RESUMO

A síndrome DRESS é uma reação adversa a medicamentos pouco conhecida dentro da prática clínica, porém com grande potencial de letalidade devido a combinação de manifestações cutâneas e envolvimento de múltiplos órgãos. Objetivo: identificar possíveis reações adversas graves e incomuns secundárias ao uso de medicações usadas frequentemente na prática clínica. Métodos: Trata-se de um relato de caso construído com base em levantamento de dados do prontuário do paciente e análise a partir de um referencial teórico para comprovação de sua relevância na prática clínica. Resultado: Enfatizou-se a importância de um reconhecimento precoce dessa condição, a fim de evitar desfechos graves

The DRESS syndrome is an adverse drug reaction that is unsual in clinical practice, but with a high potential for lethality, due to the combination of cutaneous manifestations and involvement of multiple organs. Objective: identify possible serious and unusual adverse reactions secondary to the use of medications frequently used in clinical practice. Methods: This is a case report built on the basis of data collection from the patient's medical record and analysis from a theoretical framework to prove its source in clinical practice. Outcome: The importance of early recognition of this condition was emphasized, in order to avoid serious outcomes

Assuntos

RESUMO

RESUMEN El síndrome de hipersensibilidad por fármacos, también conocido como síndrome de DRESS, es una farmacodermia grave que se caracteriza por una erupción polimorfa diseminada, fiebre y compromiso multiorgánico. Este padecimiento tiene una incidencia que oscila entre el 0,1 % y el 0,01 % de las exposiciones farmacológicas, con una probabilidad de fallecimiento de un 20 % al 30 %. Fue descrito por primera vez en el año 1936, como una reacción adversa a la fenitoína. En la actualidad se reconoce que puede estar asociado a otros fármacos como: abacavir, metronidazol, doxiciclina, isoniazida, carbamacepina, fenobarbital, beta-bloqueadores, dapsona, ranitidina, antiinflamatorios no esteroideos y el alopurinol. Se presenta un paciente de 69 años de edad que desarrolló un síndrome de DRESS secundario a alopurinol. El paciente mostró signos poco frecuentes de esta rara enfermedad: linfocitos atípicos, hepatomegalia y afección renal; falleció poco después debido a un choque séptico por estafilococo áureo.

ABSTRACT Drug hypersensitivity syndrome, also known as DRESS syndrome, is a severe pharmacodermia characterized by a polymorphous disseminated rash, fever, and multi-organ involvement. Its incidence ranges between 0.1 to 0.01% from the pharmacological exposures, with a probability of death ranging from 20 to 30%. It was first described in 1936 as an adverse reaction to phenytoin. Nowadays, it is known that it can also be associated with other drugs such as abacavir, metronidazole, doxycycline, isoniazid, carbamazepine, phenobarbital, beta-blockers, dapsone, ranitidine, nonsteroidal anti-inflammatory drugs and allopurinol. We present a 69-year-old male patient who developed a DRESS syndrome secondary to alupurinol. The patient showed unusual signs of this rare disease such as atypical lymphocytes, hepatomegaly and kidney disease; he dies shortly after from a septic shock due to Staphylococcus aureus.

Assuntos

RESUMO

Resumen: El síndrome DRESS es un reacción de hipersensibilidad a fármacos severa e idiosincrásica, caracterizada por exantema, fiebre, adenopatías, alteraciones hematológicas y afectación de varios órganos. La heterogeneidad de la manifestación clínica representa un desafío diagnóstico para el médico clínico, se requiere alto índice de sospecha y descartar un amplio espectro de diagnósticos diferenciales. Las reacciones cutáneas asociadas con fármacos pueden ser cuadros potencialmente mortales, el diagnóstico oportuno puede modificar el pronóstico del paciente. Describimos el cuadro clínico y tratamiento de un paciente de 15 años con insuficiencia renal crónica que fue hospitalizado por lesiones morbiliformes generalizadas concomitantes con fiebre, linfadenopatías, esplenomegalia y eosinofilia. Descartar procesos infecciosos, autoinmunitarios y neoplásicos fue posible con estudios complementarios; el antecedente de ingestión reciente de alopurinol y los datos clínicos y de laboratorio permitieron establecer el diagnóstico definitivo de síndrome DRESS. El paciente recibió corticoesteroides tópicos y sistémicos, las manifestaciones clínicas revirtieron a partir de la segunda semana de hospitalización. Se insiste en la importancia de la identificación de factores de riesgo asociados con la aparición de este síndrome.

Abstract: Dress syndrome is a severe and idiosyncratic reaction of hypersensitivity to drugs, characterized by rash, fever, lymphadenopathy, hematological alterations and systemic compromise, the heterogeneity of the clinical presentation represents a diagnostic challenge for the clinician, a high clinical suspicion is required and the need to rule out a wide spectrum of differential diagnoses. Cutaneous reactions associated with drugs can be potentially fatal, early diagnosis can modify the patient's prognosis. We describe the clinical case and treatment of a 15-year-old male patient with chronic renal failure who was hospitalized for generalized morbilliform lesions associated with fever, lymphadenopathy, splenomegaly and eosinophilia. Complementary studies ruled out infectious, autoimmune and neoplastic processes; the antecedent of recent intake of allopurinol together with clinical and laboratory data allowed to establish a definitive diagnosis of DRESS syndrome. Patient received topical and systemic corticosteroids, clinical manifestations reverted from the second week of hospitalization. We emphasize the importance of identifying risk factors associated with the development of this syndrome.

RESUMO

As espécies reativas de oxigênio (EROs) são radicais livres derivadas do oxigênio. O fármaco Alopurinol (ALO) possui um efeito inibidor da enzima Xantina Oxidase, uma das vias da produção de EROs. Para combater esse ataque oxidativo no nosso organismo, existe uma defesa antioxidante enzimática, composta pelas enzimas Superóxido dismutase (SOD), Catalase (CAT) e Glutationa Peroxidase (GPX). O objetivo do presente estudo foi analisar os efeitos do alopurinol na defesa antioxidante no fígado de ratos Wistar. Foram utilizados 20 ratos machos divididos em dois grupos: Controle (C) e Alopurinol (ALO). A droga foi administrada para os animais do grupo ALO, enquanto que no grupo C houve uma administração de veículo (salina), ambos durante 3 dias. Os resultados apontaram uma redução significativa na atividade das enzimas antioxidantes no grupo ALO em comparação ao grupo C. A partir desses resultados sugeriu-se que o alopurinol foi eficiente na inibição de EROs.

Reactive oxygen species (ROS) are free radicals derived from oxygen. The drug Allopurinol (ALO) has an inhibitory effect of the enzyme Xanthine Oxidase, one of the routes of ROS production. To combat this oxidative attack in our body, there is an enzymatic antioxidant defense, composed by the enzymes Superoxide dismutase (SOD), Catalase (CAT) and Glutathione Peroxidase (GPX). The aim of the present study was to analyze the effects of allopurinol on the antioxidant defense in the liver of Wistar rats. Twenty male rats were divided into two groups: Control (C) and Allopurinol (ALO). The drug was administered to the animals of the ALO group, while in group C there was a vehicle (saline) administration, both for 3 days. The results indicated a significant reduction in the activity of the antioxidant enzymes in the ALO group compared to the group C. From these results it was suggested that allopurinol was efficient in inhibiting ROS.

Assuntos

RESUMO

As espécies reativas de oxigênio (EROs) são radicais livres derivadas do oxigênio. O fármaco Alopurinol (ALO) possui um efeito inibidor da enzima Xantina Oxidase, uma das vias da produção de EROs. Para combater esse ataque oxidativo no nosso organismo, existe uma defesa antioxidante enzimática, composta pelas enzimas Superóxido dismutase (SOD), Catalase (CAT) e Glutationa Peroxidase (GPX). O objetivo do presente estudo foi analisar os efeitos do alopurinol na defesa antioxidante no fígado de ratos Wistar. Foram utilizados 20 ratos machos divididos em dois grupos: Controle (C) e Alopurinol (ALO). A droga foi administrada para os animais do grupo ALO, enquanto que no grupo C houve uma administração de veículo (salina), ambos durante 3 dias. Os resultados apontaram uma redução significativa na atividade das enzimas antioxidantes no grupo ALO em comparação ao grupo C. A partir desses resultados sugeriu-se que o alopurinol foi eficiente na inibição de EROs.(AU)

Reactive oxygen species (ROS) are free radicals derived from oxygen. The drug Allopurinol (ALO) has an inhibitory effect of the enzyme Xanthine Oxidase, one of the routes of ROS production. To combat this oxidative attack in our body, there is an enzymatic antioxidant defense, composed by the enzymes Superoxide dismutase (SOD), Catalase (CAT) and Glutathione Peroxidase (GPX). The aim of the present study was to analyze the effects of allopurinol on the antioxidant defense in the liver of Wistar rats. Twenty male rats were divided into two groups: Control (C) and Allopurinol (ALO). The drug was administered to the animals of the ALO group, while in group C there was a vehicle (saline) administration, both for 3 days. The results indicated a significant reduction in the activity of the antioxidant enzymes in the ALO group compared to the group C. From these results it was suggested that allopurinol was efficient in inhibiting ROS.(AU)

Assuntos

RESUMO

Resumen El ácido úrico es producto final del metabolismo de las purinas, transformadas finalmente a ácido úrico. No existe definición universal de hiperuricemia, en la práctica, el punto de corte es a partir de 6.8 mg/dL en plasma. Estudios experimentales han demostrado una correlación positiva lineal entre la presión arterial y las concentraciones de ácido úrico, así como disminución de las cifras tensionales al administrar tratamiento hipouricemiante con alopurinol. Se han identificado numerosos mecanismos a través de los cuales la hiperuricemia puede causar hipertensión: reducción de las concentraciones de óxido nítrico endotelial, estimulación de estrés oxidativo, expresión en las células de músculo liso del endotelio vascular de receptor URAT-1, activación del eje renina angiotensina, estimulación de la proliferación de músculo liso vascular, además, favorece la enfermedad microvascular renal. La evidencia reciente ha aportado nuevo conocimiento acerca de los múltiples mecanismos a través de los cuales el ácido úrico tendría un papel preponderante en la hipertensión arterial sistémica y en múltiples alteraciones metabólicas; sin embargo, hace falta desarrollar estudios clínicos a gran escala, bien diseñados, que comprueben de manera más contundente estas teorías, antes de considerar tratamientos enfocados en el manejo de la hiperuricemia asintomática en la práctica clínica diaria.

Abstract Uric acid is the end product of purine metabolism, ultimately converted to uric acid. There is no universal definition of hyperuricemia, in practice, the cutoff point is from 6.8mg/dL in plasma. The relationship between hyperuricemia and hypertension has been demonstrated in many experimental studies. Experimental studies have shown a linear positive correlation between blood pressure and uric acid levels, as well as a decrease in blood pressure figures with therapy with allopurinol. Numerous mechanisms have been identified through which hyperuricemia can cause hypertension: reduction of endothelial nitric oxide levels, stimulation of oxidative stress, expression in smooth muscle cells of the vascular endothelium of URAT-1 receptor, activation of the renin-angiotensin axis, stimulation of vascular smooth muscle proliferation also favors the development of renal microvascular disease. Recent evidence has provided new insight into the multiple mechanisms through which UA would play a major role both in systemic arterial hypertension and in multiple metabolic alterations; however, large-scale, well-designed clinical studies are needed, which prove more conclusively these theories, before considering therapies focused on the management of asymptomatic hyperuricemia in daily clinical practice

RESUMO

A Leishmaniose é uma doença infecciosa, não contagiosa, causada por parasitas do gênero Leishmania, disseminada por mosquitos flebotomíneos, possui alta mobilidade e consequente mortalidade por todo o mundo, principalmente sobre países subtropicais como o Brasil. O tratamento normalmente é de longo prazo, com alto custo e com prejuizo à saude do hospedeiro pela toxidade das medidações quimioterápicas normalmente utilizadas. Sendo assim, este relato de caso de 2 animais, diagnosticados clinicamente e sorologicamente como positivos para Leishmaniose, demonstrou a eficácia de utilização de substancias naturais baseados em uma medicina veterinária integrativa no tratamento complementar da Leishmaniose. Para tanto os animais foram tratados como o gás ozônio (Ozonioterapia) e com o cogumelo do sol (Agaricus blazei Murill) sendo que após 5 meses de tratamento, foi constatado o desaparecimento dos sinais clínicos com diminuição da titulação sorológica para Leishmaniose em um dos animais e remissão em outro.

Assuntos

RESUMO

A Leishmaniose é uma doença infecciosa, não contagiosa, causada por parasitas do gênero Leishmania, disseminada por mosquitos flebotomíneos, possui alta mobilidade e consequente mortalidade por todo o mundo, principalmente sobre países subtropicais como o Brasil. O tratamento normalmente é de longo prazo, com alto custo e com prejuizo à saude do hospedeiro pela toxidade das medidações quimioterápicas normalmente utilizadas. Sendo assim, este relato de caso de 2 animais, diagnosticados clinicamente e sorologicamente como positivos para Leishmaniose, demonstrou a eficácia de utilização de substancias naturais baseados em uma medicina veterinária integrativa no tratamento complementar da Leishmaniose. Para tanto os animais foram tratados como o gás ozônio (Ozonioterapia) e com o cogumelo do sol (Agaricus blazei Murill) sendo que após 5 meses de tratamento, foi constatado o desaparecimento dos sinais clínicos com diminuição da titulação sorológica para Leishmaniose em um dos animais e remissão em outro.(AU)

Assuntos

RESUMO

Objetivo: Determinar el efecto del alopurinol en las adherencias peritoneales al colocar una malla de polipropileno. Sede: Cirugía Experimental de la Universidad de Guanajuato. Diseño: Estudio experimental, prospectivo, comparativo, controlado, doble ciego, con asignación al azar. Análisis estadístico: χ². Material y métodos: Se compararon dos grupos de 30 ratas Wistar cada uno, a quienes se les colocó una malla de polipropileno: el grupo A, sin tratamiento versus el grupo B, alopurinol a 25 mg/kg/día por sonda orogástrica. Resultados: Este estudio determinó que la prevalencia de adherencias protésicas-peritoneales viscerales en ratas Wistar, al colocar una malla de polipropileno, es del 100% sin tratamiento y con alopurinol. Conclusiones: No obtuvimos diferencia estadística del efecto beneficioso del alopurinol en la prevención de adherencias, esto puede hablarnos de que la acción del alopurinol sólo se ejerce en la prevención de adherencias cuando su etiología es la isquemia y no debido a la presencia de reacción a cuerpo extraño de tipo granulomatoso.

Objective: To determine the effect of allopurinol on peritoneal adhesions when placing a polypropylene mesh. Setting: Experimental Surgery Unit of the University of Guanajuato, México. Design: Experimental, prospective, comparative, controlled, double-blinded, randomized assignment study. Statistical analysis: χ². Material and Methods: We compared two groups of 30 Wistar rats each, in which we placed a polypropylene mesh: Group A, without treatment, versus group B with allopurinol at mg/kg per day administered through an orogastric catheter. Results: This study determined that the prevalence of visceral peritoneal-prosthetic adhesions in Wistar rats when placing a polypropylene mesh is of 100% with and without allopurinol treatment. Conclusions: We did not obtain statistical differences of the beneficial effect of allopurinol in preventing adhesions, this can indicate that allopurinol's effect is only exerted in preventing adhesions when they are due to ischemia but not when they are caused by a granulomatous-type foreign body reaction.

RESUMO

O controle de qualidade de matérias-primas é imprescindível, pois visa assegurar a qualidade do produto acabado. O objetivo do trabalho foi avaliar a qualidade físico-química e farmacotécnica de matérias-primas de alopurinol, fármaco utilizado para a prevenção e o tratamento de crises de gota, amplamente prescrito e produzido por indústrias e farmácias magistrais. As amostras (A, B, C e D) de alopurinol oriundas de diferentes fornecedores foram submetidas a ensaios farmacopeicos (características organolépticas; solubilidade; ensaios de identificação: teste de precipitação e varredura no UV; ensaios de pureza: limpidez de solução, perda por dessecação, cinzas sulfatadas; doseamento), análise térmica (DSC, TG), análise granulométrica e determinação das propriedades de fluxo (ângulo de repouso, densidade bruta e de compactação, fator de Hausner, índice de compressibilidade e compactabilidade). As amostras foram aprovadas em todos os ensaios farmacopeicos. Nas curvas de DSC, o ponto de fusão foi de cerca de 380 °C para todas as amostras e, após a fusão houve a degradação, confirmada pelas curvas TG, com uma perda de massa de aproximadamente 100 %. A partir da distribuição granulométrica as amostras A e B foram classificadas como pós finos e as C e D como finíssimos. Os valores de ângulo de repouso caracterizaram as amostras A, B, C e D como de fluxo fraco e, o fator de Hausner e índice de compressibilidade caracterizaram as amostras como amostras de fluxo bastante deficiente. Os ensaios demonstraram-se úteis para avaliar a qualidade das amostras. A adição de adjuvantes apropriados durante o preparo das formulações de alopurinol é essencial para melhoramento do fluxo.

The quality control of raw materials is intended to ensure the quality of the finished product. The objective of this study was to carry out physicochemical and pharmacotechnical assessments of allopurinol raw materials. This drug is widely prescribed for the prevention and treatment of gout and is produced both by drug manufacturers and compounding pharmacies. Samples (A, B, C and D) from 4 different suppliers were subjected to pharmacopoeial testing (organoleptic characteristics; solubility; identification tests: precipitation and scanning UV; purity tests: clarity of solution, loss on drying, sulphated ash; assay), thermal analysis (DSC, TG), particle size analysis and flow property tests (angle of repose, bulk density and tapped density, Hausner ratio, compressibility and compactibility). The samples were approved in all the pharmacopoeial tests. In the DSC curves, the melting point was about 380 °C for all samples and after fusion there was degradation, confirmed by TG, with a weight loss of approximately 100%. From the particle size distributions, samples A and B were classified as fine powders and C and D as very fine powders. The angles of repose characterized the samples A, B, C and D as having weak flow, while the Hausner ratio and compressibility index indicated that they had very, very poor flow. The tests proved useful for assessing the quality of the samples and showed that appropriate adjuvants need to be added to the allopurinol formulations to improve the flow.

Assuntos

RESUMO

Objetivo. Evaluar el efecto protector contra la lesión por isquemia-reperfusión intestinal del pretratamiento con alopurinol en ratas. Materiales y métodos. Se llevó a cabo un experimento controlado en animales. Un grupo de 10 ratas Wistar de características morfométricas comparables se mantuvo en bioterio bajo condiciones controladas por tres días. A cinco animales se les administró 50 mg/kg diarios de alopurinol por vía oral durante los tres días y, una dosis adicional, antes de inducir isquemia intestinal por ligadura quirúrgica durante 60 minutos seguida de 60 minutos de reperfusión. El otro grupo de cinco ratas no recibió el medicamento. Se hizo el análisis histológico de la mucosa intestinal al final del experimento por medio de la clasificación de Chou y se tomaron hemocultivos de la cavidad cardiaca. Resultados. Se encontraron hemocultivos positivos en 20 % de los animales pretratados con alopurinol, en comparación con el 100 % de las ratas control (p<0,0001). Se evidenció lesión profunda en la mucosa intestinal en todos los casos. La administración previa a la injuria de alopurinol redujo significativamente la lesión por isquemia-reperfusión (p<0,001). Conclusiones. La administración de alopurinol antes de la isquemia intestinal, reduce los cambios morfológicos ocasionados por isquemia-reperfusión. El efecto benéfico se demostró con el pretratamiento por tres días.

Objective: To evaluate the protective effect of pretreatment with allopurinol in an intestinal ischemia-reperfusion injury rat model. Materials and methods: A controlled animal trial was conducted; 10 Wistar rats were kept under controlled conditions for three days. One group (n=5) received allopurinol 50 mg/kg per day for the 3-day period and an additional dose immediately prior to surgical mesenteric artery clamping (60 minutes) and reperfusion (60 minutes). The other group (n=5) did not receive the medication. Hystologic analysis of intestinal mucosa by means of Chou grading system was performed, and blood cultures from the heart were withdrawn. Results: Positive blood cultures were found in 20% of the allopurinol group as compared with 100% in the control group (p<0.0001). Deep mucosal lesion was evidence in all cases. Allopurinol pretreatment reduced significantly the ischemia-reperfusion injury (p<0.001). Conclusions: Allopurinol administration prior to intestinal ischemia ameliorated morphologic changes related to the ischemia-reperfusion process. The beneficial effect of allopurinol was demonstrated with pretreatment for three days.

Assuntos

RESUMO

JUSTIFICATIVA E OBJETIVOS: A necrólise epidérmica tóxica (NET) é uma farmacodermia rara, com possibilidade de morte pelas suas complicações. O objetivo deste relato foi apresentar um caso desta farmacodermia devido ao uso de alopurinol, um medicamento de uso comum. RELATO DO CASO: Paciente do sexo masculino, 65 anos, apresentou o quadro após utilização de alopurinol concomitante a uso pregresso de grande quantidade de álcool diariamente,anti-hipertensivos e diclofenaco irregularmente. Admitido no serviço com lesões descamativas de aspecto de grande queimado em mais de 50% do corpo, dispneia, taquicardia, hematúria macroscópica e conjuntivite bolhosa. O paciente foi tratado na unidade de terapia intensiva, com suspensão da medicação e teve boa evolução, com resolução total do quadro após 32 dias do seu início. CONCLUSÃO: O tratamento para NET ainda não é consensual, assim como a suspensão do medicamento que a originou. Entretanto, cuidados preferencialmente em unidades de queimado e prevenção e profilaxia com antibióticos para infecções são essenciais para uma boa evolução. O conhecimento médico sobre esta rara síndrome e sobre o seu tratamento adequado pode fazer a diferença no diagnóstico diferencial e na sua conduta.

BACKGROUND AND OBJECTIVES: Epidermal toxic necrolysis (TEN) is a rare dermatological reaction to drugs, feasible to death due to medical complications. This article reports a caseof such reaction due to the use of allopurinol, a rather common drug.CASE REPORT: Male patient, 65 year old, presenting the reaction after the use of allopurinol along with previous daily ingestion of great amounts of alcohol, antihypertensive medications, and irregular diclofenac. He was admitted with desquamating lesions similar to skin burns in over 50% of body surface, dyspnea, tachycardia, macroscopic hematuria and bullosa conjunctivitis.The patient was taken care of in the Intensive Care Unit, his medication was suspended and he improved importantly, resolving the reaction after 32 days since its initial development. CONCLUSION: There is no consensus for the treatment of TEN, a neither as for the medication suspension. However, intensive care in burns unit and prevention and prophylaxis with antibiotics for infections are essential for good resolution. Knowing such rare syndrome and its adequate treatment might makethe difference during the differential diagnosis and conducts.

Assuntos